Brief: Theranexus And BBDF Obtain European Orphan Medicinal Product Designation For BBDF-101 In Batten Disease
21/10/2020 17:11
Oct 21 (Reuters) - Theranexus SA ALTHX.PA :
* ANNOUNCED EUROPEAN COMMISSION'S DECISION TO AWARD "ORPHAN
MEDICINAL PRODUCT" DESIGNATION TO TWO ACTIVE INGREDIENTS,
TREHALOSE AND MIGLUSTAT, USED IN DRUG CANDIDATE BBDF-101 FOR
BATTEN DISEASE
* UNDER AGREEMENT BETWEEN THERANEXUS AND BBDF, THERANEXUS
HAS
EXCLUSIVE, GLOBAL LICENSE FOR DEVELOPMENT AND COMMERCIAL USE OF
ITS DRUG CANDIDATE BBDF-101 FOR JUVENILE BATTEN DISEASE
Source text for Eikon: ID:nACT65687
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease